Abstract
The adrenergic receptors are among the best characterized G protein-coupled receptors (GPCRs) and knowledge on this receptor family has provided several important paradigms about GPCR function and regulation. One of the most recent paradigms initially supported by studies on adrenergic receptors is that both βarrestins and G proteincoupled receptors themselves can act as scaffolds binding a variety of proteins and this can result in growing complexity of the receptor-mediated cellular effects. In this review we will briefly summarize the main features of βarrestin binding to the adrenergic receptor subtypes and we will review more in detail the main proteins found to selectively interact with distinct AR subtype. At the end, we will review the main findings on oligomerization of the AR subtypes.
Keywords: adrenergic receptor subtypes, signaling complexes, arrestins, receptor, oligomerization, protein-protein interactions, catecholamines, G protein coupled receptors, GPCR, beta-AR, receptor oligomerization
Current Drug Targets
Title: Protein-Protein Interactions at the Adrenergic Receptors
Volume: 13 Issue: 1
Author(s): Susanna Cotecchia, Laura Stanasila and Dario Diviani
Affiliation:
Keywords: adrenergic receptor subtypes, signaling complexes, arrestins, receptor, oligomerization, protein-protein interactions, catecholamines, G protein coupled receptors, GPCR, beta-AR, receptor oligomerization
Abstract: The adrenergic receptors are among the best characterized G protein-coupled receptors (GPCRs) and knowledge on this receptor family has provided several important paradigms about GPCR function and regulation. One of the most recent paradigms initially supported by studies on adrenergic receptors is that both βarrestins and G proteincoupled receptors themselves can act as scaffolds binding a variety of proteins and this can result in growing complexity of the receptor-mediated cellular effects. In this review we will briefly summarize the main features of βarrestin binding to the adrenergic receptor subtypes and we will review more in detail the main proteins found to selectively interact with distinct AR subtype. At the end, we will review the main findings on oligomerization of the AR subtypes.
Export Options
About this article
Cite this article as:
Cotecchia Susanna, Stanasila Laura and Diviani Dario, Protein-Protein Interactions at the Adrenergic Receptors, Current Drug Targets 2012; 13(1) . https://dx.doi.org/10.2174/138945012798868489
DOI https://dx.doi.org/10.2174/138945012798868489 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |

- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Reactive Oxygen Species in Pathogenesis of Atherosclerosis
Current Pharmaceutical Design Beneficial and Detrimental Effects of Antioxidants Use in Sports: How is it Balanced?
Current Nutraceuticals The Heart and Brain Imaging in Lone Atrial Fibrillation – Are We Surprised?
Current Pharmaceutical Design Translational Application of Combining Magnetic Resonance Imaging and Biomechanical Analysis in Carotid Plaque Vulnerability Assessment
Recent Patents on Medical Imaging Genetics and Bioenergetics of Mitochondria Influencing the Etiology and Pharmacology of Steroidal Hormones
Current Pharmacogenomics Modulation of Individual Susceptibility to the No-Reflow Phenomenon after Acute Myocardial Infarction
Current Pharmaceutical Design Retigabine: Could it be the Next Broad-Spectrum Antiepileptic Drug?
Current Drug Therapy Ximelagatran - A Promising New Drug in Thromboembolic Disorders
Current Pharmaceutical Design Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Interstitial Lung Disease in Systemic Sclerosis: Pathophysiology, Current and New Advances in Therapy
Inflammation & Allergy - Drug Targets (Discontinued) Regulation of Mitochondrial Function and its Impact in Metabolic Stress
Current Medicinal Chemistry An Update on Peptide Drugs for Voltage-Gated Calcium Channels
Recent Patents on CNS Drug Discovery (Discontinued) Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis
Current Pharmaceutical Design Complications of Infective Endocarditis
Cardiovascular & Hematological Disorders-Drug Targets Effects of Glucagon-like Peptide-1 Receptor Agonists and Sodium-glucose Cotransporter 2 Inhibitors on Cardiorenal and Metabolic Outcomes in People Without Diabetes
Current Pharmaceutical Design Cyclooxygenase Inhibitors: Instrumental Drugs to Understand Cardiovascular Homeostasis and Arterial Thrombosis
Cardiovascular & Hematological Disorders-Drug Targets The Basic Mechanism of Hair Growth Stimulation by Adipose-derived Stem Cells and Their Secretory Factors
Current Stem Cell Research & Therapy Therapy of XDR TB with Thioridazine a Drug Beyond Patent Protection but Eligible for Patent “As New Use”
Recent Patents on Anti-Infective Drug Discovery Novel Strategies in Cancer Therapeutics: Targeting Enzymes Involved in Cell Cycle Regulation and Cellular Proliferation
Current Cancer Drug Targets Pharmacokinetics of CNT-based Drug Delivery Systems
Current Drug Metabolism